AKt as a therapeutic target for cancer

Mengqiu Song, Ann M. Bode, Zigang Dong, Mee Hyun Lee

Research output: Contribution to journalReview article

4 Citations (Scopus)

Abstract

Many cellular processes in cancer are attributed to kinase abnormal overexpression or activation of AKT has been signaling networks. V-akt murine thymoma viral oncogene observed in many cancers, including ovarian, lung, and pan-homolog (AKT) plays a major role in the PI3K/AKT signaling creatic cancers, and is associated with increased cancer cell pathways. AKT is activated by PI3K or phosphoinositide-proliferation and survival. Therefore, targeting AKT could dependent kinases (PDK) as well as growth factors, inflam-provide an important approach for cancer prevention and mation, and DNA damage. Signal transduction occurs through therapy. In this review, we discuss the rationale for targeting downstream effectors such as mTOR, glycogen synthase kinase AKT and also provide details regarding synthetic and natural 3 beta (GSK3b), or forkhead box protein O1 (FOXO1). The AKT-targeting compounds and their associated studies.

Original languageEnglish (US)
Pages (from-to)1019-1031
Number of pages13
JournalCancer Research
Volume79
Issue number6
DOIs
StatePublished - Jan 1 2019

Fingerprint

Phosphatidylinositol 3-Kinases
Neoplasms
Phosphotransferases
Glycogen Synthase Kinases
Thymoma
Therapeutics
Phosphatidylinositols
Oncogenes
Ovarian Neoplasms
DNA Damage
Signal Transduction
Intercellular Signaling Peptides and Proteins
Lung
Forkhead Box Protein O1

PubMed: MeSH publication types

  • Journal Article
  • Review

Cite this

AKt as a therapeutic target for cancer. / Song, Mengqiu; Bode, Ann M.; Dong, Zigang; Lee, Mee Hyun.

In: Cancer Research, Vol. 79, No. 6, 01.01.2019, p. 1019-1031.

Research output: Contribution to journalReview article

Song, Mengqiu ; Bode, Ann M. ; Dong, Zigang ; Lee, Mee Hyun. / AKt as a therapeutic target for cancer. In: Cancer Research. 2019 ; Vol. 79, No. 6. pp. 1019-1031.
@article{c88197a1eb354c1199da438dcba3c198,
title = "AKt as a therapeutic target for cancer",
abstract = "Many cellular processes in cancer are attributed to kinase abnormal overexpression or activation of AKT has been signaling networks. V-akt murine thymoma viral oncogene observed in many cancers, including ovarian, lung, and pan-homolog (AKT) plays a major role in the PI3K/AKT signaling creatic cancers, and is associated with increased cancer cell pathways. AKT is activated by PI3K or phosphoinositide-proliferation and survival. Therefore, targeting AKT could dependent kinases (PDK) as well as growth factors, inflam-provide an important approach for cancer prevention and mation, and DNA damage. Signal transduction occurs through therapy. In this review, we discuss the rationale for targeting downstream effectors such as mTOR, glycogen synthase kinase AKT and also provide details regarding synthetic and natural 3 beta (GSK3b), or forkhead box protein O1 (FOXO1). The AKT-targeting compounds and their associated studies.",
author = "Mengqiu Song and Bode, {Ann M.} and Zigang Dong and Lee, {Mee Hyun}",
year = "2019",
month = "1",
day = "1",
doi = "10.1158/0008-5472.CAN-18-2738",
language = "English (US)",
volume = "79",
pages = "1019--1031",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "6",

}

TY - JOUR

T1 - AKt as a therapeutic target for cancer

AU - Song, Mengqiu

AU - Bode, Ann M.

AU - Dong, Zigang

AU - Lee, Mee Hyun

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Many cellular processes in cancer are attributed to kinase abnormal overexpression or activation of AKT has been signaling networks. V-akt murine thymoma viral oncogene observed in many cancers, including ovarian, lung, and pan-homolog (AKT) plays a major role in the PI3K/AKT signaling creatic cancers, and is associated with increased cancer cell pathways. AKT is activated by PI3K or phosphoinositide-proliferation and survival. Therefore, targeting AKT could dependent kinases (PDK) as well as growth factors, inflam-provide an important approach for cancer prevention and mation, and DNA damage. Signal transduction occurs through therapy. In this review, we discuss the rationale for targeting downstream effectors such as mTOR, glycogen synthase kinase AKT and also provide details regarding synthetic and natural 3 beta (GSK3b), or forkhead box protein O1 (FOXO1). The AKT-targeting compounds and their associated studies.

AB - Many cellular processes in cancer are attributed to kinase abnormal overexpression or activation of AKT has been signaling networks. V-akt murine thymoma viral oncogene observed in many cancers, including ovarian, lung, and pan-homolog (AKT) plays a major role in the PI3K/AKT signaling creatic cancers, and is associated with increased cancer cell pathways. AKT is activated by PI3K or phosphoinositide-proliferation and survival. Therefore, targeting AKT could dependent kinases (PDK) as well as growth factors, inflam-provide an important approach for cancer prevention and mation, and DNA damage. Signal transduction occurs through therapy. In this review, we discuss the rationale for targeting downstream effectors such as mTOR, glycogen synthase kinase AKT and also provide details regarding synthetic and natural 3 beta (GSK3b), or forkhead box protein O1 (FOXO1). The AKT-targeting compounds and their associated studies.

UR - http://www.scopus.com/inward/record.url?scp=85062950244&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85062950244&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-18-2738

DO - 10.1158/0008-5472.CAN-18-2738

M3 - Review article

VL - 79

SP - 1019

EP - 1031

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 6

ER -